List of Excipients in Branded Drug GRANISETRON HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing GRANISETRON HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
West-Ward Pharmaceuticals Corp	granisetron hydrochloride	0054-0143	CELLULOSE, MICROCRYSTALLINE
West-Ward Pharmaceuticals Corp	granisetron hydrochloride	0054-0143	HYPROMELLOSES
West-Ward Pharmaceuticals Corp	granisetron hydrochloride	0054-0143	LACTOSE
West-Ward Pharmaceuticals Corp	granisetron hydrochloride	0054-0143	MAGNESIUM STEARATE
West-Ward Pharmaceuticals Corp	granisetron hydrochloride	0054-0143	SODIUM STARCH GLYCOLATE TYPE A POTATO

What are the Most Frequently-Used Excipients in GRANISETRON HYDROCHLORIDE?

# Of NDCs	Excipient
2	ANHYDROUS CITRIC ACID
3	BENZYL ALCOHOL
7	CELLULOSE, MICROCRYSTALLINE
10	CITRIC ACID MONOHYDRATE
11	HYDROCHLORIC ACID

Granisetron Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 26, 2026

Granisetron hydrochloride is an established 5-HT3 antagonist used mainly for chemotherapy-induced nausea and vomiting (CINV), with additional use in postoperative nausea and vomiting (PONV) and radiation-induced nausea and vomiting in selected markets. Its active pharmaceutical ingredient is generic and clinically mature. Commercial value therefore depends less on new chemical entity protection and more on formulation differentiation, administration convenience, hospital procurement, device performance, and regulatory pathway selection.

The strongest excipient opportunities are:

1. Oral solid formulations with improved swallowing, disintegration, and low-dose content uniformity.
2. Preservative-free parenteral products with robust pH and container compatibility.
3. Transdermal systems that extend dosing over several days of chemotherapy.
4. Ready-to-use products that reduce pharmacy preparation and administration time.
5. Specialty formulations for patients unable to swallow or those with chemotherapy-associated gastrointestinal dysfunction.

What is granisetron hydrochloride used for?

Granisetron hydrochloride selectively blocks 5-HT3 serotonin receptors involved in emesis. The drug is available in oral, injectable, and transdermal dosage forms.

Product category	Typical use	Commercial role
Immediate-release tablets	Prevention of CINV	Generic outpatient and hospital product
Oral solution or liquid	Patients unable to swallow tablets	Niche pediatric, geriatric, and supportive-care opportunity
Intravenous injection	CINV and PONV	Hospital and oncology procurement
Transdermal patch	Prevention of CINV during multiday chemotherapy	Differentiated specialty product
Orally disintegrating tablet	Potential convenience product	Development opportunity, subject to regulatory and market validation

Granisetron hydrochloride is generally suitable for aqueous formulation because the salt has substantially better water solubility than the free base. The low dose creates a different technical problem: blend uniformity and dose accuracy are more important than high drug loading.

Which excipients are used in granisetron hydrochloride tablets?

Commercial immediate-release tablets commonly use lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hypromellose, magnesium stearate, and coating materials. The exact composition varies by manufacturer and strength. The Kytril label identifies excipients including lactose, microcrystalline cellulose, sodium starch glycolate, hypromellose, magnesium stearate, titanium dioxide, and polyethylene glycol in the coated tablet system.[1]

Functional role of the principal excipients

Excipient class	Candidate materials	Function in granisetron tablets
Diluent	Lactose monohydrate, microcrystalline cellulose, mannitol	Controls tablet mass and improves manufacturability
Disintegrant	Sodium starch glycolate, crospovidone, croscarmellose sodium	Accelerates tablet breakup and drug release
Binder	Hypromellose, povidone, copovidone	Improves granule and tablet strength
Lubricant	Magnesium stearate, sodium stearyl fumarate	Controls ejection and tooling friction
Glidant	Colloidal silicon dioxide	Improves powder flow
Film former	Hypromellose	Protects the tablet and supports identification
Plasticizer	Polyethylene glycol	Improves coating flexibility
Opacifier or colorant	Titanium dioxide, iron oxides	Supports appearance and product differentiation

The main excipient risks are not chemical instability but poor content uniformity, over-lubrication, delayed disintegration, and variable dissolution. Granisetron hydrochloride tablets contain a small amount of active ingredient relative to the total tablet mass. Direct compression can work if the active is engineered for flow and particle-size control. Wet granulation can improve uniformity but adds water, drying, and process-development complexity.

How should an excipient strategy be designed for immediate-release tablets?

A practical strategy is to use a high-flow diluent system with a rapid disintegrant and controlled lubrication.

Option 1: Lactose and microcrystalline cellulose platform

This is the closest approach to established commercial products. It offers broad supplier availability and a familiar regulatory profile. The main risks are lactose-related labeling considerations and variability caused by raw-material particle size.

Option 2: Mannitol-based platform

Mannitol can support a cleaner taste profile and a better foundation for chewable or orally disintegrating dosage forms. It generally costs more than standard lactose systems and may require careful control of compactability.

Option 3: Coprocessed excipient platform

Coprocessed microcrystalline cellulose systems can improve flow and compression in low-dose formulations. They may reduce process steps and support direct compression, but the excipient change must be assessed for impact on dissolution, bioequivalence, and manufacturing scale-up.

Option 4: Low-moisture formulation

A low-moisture blend using microcrystalline cellulose, anhydrous lactose or mannitol, crospovidone, and sodium stearyl fumarate can reduce moisture exposure. This approach is useful where the selected granisetron hydrochloride grade shows moisture sensitivity or where coating stability is a concern.

The commercial objective should be a robust, low-cost tablet with rapid disintegration rather than a complex excipient system that creates avoidable regulatory or supply-chain risk.

What excipients are suitable for granisetron hydrochloride oral liquids?

An oral liquid can address patients who cannot swallow tablets, but the formulation must control pH, taste, microbial growth, and dose uniformity.

Potential components include:

• Purified water as the vehicle.
• Citrate or phosphate buffer for pH control.
• Glycerin, sorbitol, or a low concentration of propylene glycol for mouthfeel and solubilization.
• Sucralose, sodium saccharin, or other sweeteners.
• Flavoring agents compatible with the drug and preservative system.
• Sodium benzoate or potassium sorbate where permitted by the target market.
• A suitable viscosity modifier, such as hypromellose or xanthan gum, if suspension or dose-holding characteristics require it.

A clear solution is commercially preferable to a suspension because it reduces shake-well errors and improves dose reproducibility. The formulation should avoid unnecessary surfactants unless they materially improve solubility or wetting. The main development risk is taste. 5-HT3 antagonists can produce an unpleasant oral sensory profile, making flavor masking and viscosity control important.

An oral liquid could be positioned for oncology clinics, home-care use, institutional pharmacies, and patients receiving oral or ambulatory chemotherapy. It would likely use an abbreviated regulatory pathway if it is pharmaceutically equivalent to an approved reference product. A materially different concentration, dosing device, or clinical positioning could require additional studies.

What excipients are used in granisetron hydrochloride injection?

Granisetron injection products use aqueous vehicles and tonicity or pH-control excipients. Approved labels describe granisetron hydrochloride injection as a sterile solution for intravenous administration, with sodium chloride or other formulation components depending on the product.[2,3]

Key formulation requirements are:

• Clear solution with no visible particulate matter.
• Stable pH across shelf life.
• Appropriate osmolality for intravenous administration.
• Compatibility with glass or polymer containers.
• Low extractables and leachables.
• Sterility assurance without compromising stability.
• Compatibility with common infusion fluids.

A preservative-free single-dose vial or ready-to-use premixed bag is strategically preferable for oncology hospitals. Multidose presentations may reduce packaging cost but create preservative, microbial, and institutional-use constraints.

Commercial opportunity in injectable products

The injectable market is mature and price-sensitive. Differentiation can come from:

• Ready-to-administer bags.
• Prefilled syringes for PONV.
• Small-volume formats that reduce medication waste.
• Barcoded unit-dose packaging.
• Latex-free and preservative-free configurations.
• Extended in-use stability after dilution.
• Compatibility with automated dispensing systems.

The most defensible commercial advantage is workflow reduction. A hospital product that eliminates vial withdrawal, dilution, labeling, and waste can compete even when the active ingredient is commoditized.

What excipients and materials are used in granisetron transdermal patches?

Sancuso is a transdermal granisetron system approved for prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy administered over three to five consecutive days.[4] The system releases granisetron over a multiday period and uses an adhesive matrix or related transdermal construction rather than conventional tablet excipients.

Relevant material categories include:

Patch component	Technical function
Drug-containing adhesive	Holds granisetron and controls release
Acrylic or related pressure-sensitive adhesive	Provides skin adhesion and may act as the drug matrix
Backing layer	Protects the system from the environment
Release liner	Covers the adhesive before application
Permeation-control materials	Adjust delivery through the skin
Stabilizers	Limit degradation or crystallization where required

Transdermal development is more complex than tablet development. The key variables are drug solubility in the adhesive, crystallization control, skin permeation, adhesion over several days, residual drug content, temperature sensitivity, and removal performance.

A successful transdermal product must maintain delivery despite sweating, movement, bathing, body-hair variation, and changes in skin condition. The adhesive is therefore both an excipient and a critical performance component.

What formulation patents protect granisetron hydrochloride products?

The original granisetron compound and conventional dosage forms are mature technologies. The stronger patent opportunities are usually formulation-specific rather than molecule-specific.

Potential claim areas include:

• Transdermal delivery systems.
• Adhesive compositions containing granisetron.
• Multiday release profiles.
• Patch construction and backing layers.
• Crystallization suppression.
• Improved skin adhesion.
• Oral disintegrating tablets.
• Taste-masked granisetron particles.
• Long-term stable liquid formulations.
• Ready-to-use injectable presentations.
• Container-closure systems and administration devices.
• Manufacturing processes that improve content uniformity.

The Orange Book should be reviewed for current listed patents and regulatory exclusivities for branded granisetron products, including Sancuso.[5] Patent status can differ by dosage form and reference product. A patent covering a transdermal system does not necessarily block an immediate-release tablet or a conventional injection.

Patent-strength assessment

Asset type	Typical patent strength	Commercial relevance
Basic granisetron composition	Low for new entrants	Active ingredient is mature
Conventional tablet composition	Low to moderate	Vulnerable to design-around
Specific ODT or taste-masked formulation	Moderate	Can support differentiated 505(b)(2) product
Transdermal adhesive system	Moderate to strong	Greater technical barriers and narrower design space
Ready-to-use injection	Moderate	Protection depends on formulation and device claims
Manufacturing process	Moderate	Valuable if it solves content-uniformity or scale-up problems
Device-integrated delivery system	Moderate to strong	Can create product-specific barriers

A patent estate is strongest when formulation claims are supported by comparative data showing improved adhesion, stable delivery, lower variability, better tolerability, or reduced administration burden.

When does granisetron lose exclusivity?

Granisetron has no meaningful new chemical entity exclusivity remaining in the United States. Kytril received FDA approval in the 1990s, and generic oral and injectable products have been marketed for years.[1,6]

The relevant exclusivity questions now concern individual products:

• Tablet and injection products are generally exposed to ANDA competition.
• Transdermal products may retain product-specific patent barriers depending on the current Orange Book listing.
• New dosage forms may qualify for three-year exclusivity if approval is based on new clinical investigations essential to approval.
• Orphan-drug exclusivity is generally not the primary protection mechanism for standard granisetron products.
• Pediatric exclusivity, if awarded for a specific product, is product- and date-specific.

The commercial protection period for a new granisetron formulation will therefore depend on formulation patents, regulatory exclusivity, manufacturing know-how, and market access contracts rather than on the original active ingredient.

Which companies are challenging granisetron products?

Generic manufacturers have long supplied granisetron tablets and injections in the United States and other regulated markets. The competitive field includes generic drug manufacturers, hospital suppliers, contract manufacturers, and branded specialty companies.

Competition is strongest in:

• Low-cost injectable vials.
• Standard oral tablets.
• Hospital tenders.
• Products supplied through group purchasing organizations.

Competition is weaker in:

• Multiday transdermal delivery.
• Ready-to-use oncology presentations.
• Pediatric or geriatric liquids.
• Taste-masked oral products.
• Products with integrated adherence or administration features.

Paragraph IV litigation is most relevant when a generic applicant challenges a currently listed patent for a branded transdermal or differentiated formulation. Conventional granisetron tablets and injections generally present lower litigation exposure because the products are mature and multiple suppliers exist. Current litigation and settlement terms must be checked against the Federal Court docket, FDA Orange Book, and product-specific ANDA records.[5,7]

What is the FDA regulatory status of granisetron formulations?

Granisetron is an FDA-approved antiemetic available through multiple dosage forms. FDA-approved products include oral tablets, intravenous products, and a transdermal system.[1-4]

Regulatory pathway comparison

Product concept	Likely U.S. pathway	Principal evidence burden
Conventional tablet equivalent	ANDA under section 505(j)	Pharmaceutical equivalence and bioequivalence
Conventional injection equivalent	ANDA under section 505(j)	Sterility, sameness, quality, and labeling
New oral liquid	ANDA or 505(b)(2)	Equivalence, stability, dosing-device validation
Orally disintegrating tablet	505(b)(2) or ANDA depending on sameness	Bioequivalence, disintegration, patient-use data
New transdermal system	505(b)(2)	Clinical bridging, adhesion, delivery, safety
Ready-to-use infusion product	505(j) or 505(b)(2)	Compatibility, stability, container and administration data

A 505(b)(2) strategy is most attractive when the product has a meaningful clinical or administration advantage. A routine excipient substitution without a commercial benefit may not justify the additional regulatory cost.

How can excipients create commercial differentiation?

Excipients can support a product claim only when they produce measurable performance or patient benefits.

High-value differentiation areas

1. Reduced dosing burden: A multiday patch can reduce repeated oral or intravenous dosing.
2. Improved administration: An oral liquid or orally disintegrating tablet can help patients with dysphagia.
3. Faster hospital workflow: Ready-to-use injections can reduce preparation steps.
4. Improved adherence: A patch can provide visible treatment status during chemotherapy.
5. Better tolerability: Taste masking and lower excipient burden can improve acceptance.
6. Supply resilience: Multiple qualified suppliers for critical excipients reduce manufacturing disruption.
7. Cold-chain reduction: A stable room-temperature product can lower distribution cost.

The best commercial strategy is usually not a novel excipient for its own sake. It is an excipient system tied to a specific customer problem.

What generic entry risks exist for granisetron products?

Generic entry risk is high for standard tablets and injections. A new entrant must compete on price, supply reliability, contract access, and quality performance.

Transdermal competition has a different profile. The technical barriers include:

• Drug loading in the adhesive.
• Skin flux reproducibility.
• Multiday adhesion.
• Crystallization during storage.
• Residual drug and dose uniformity.
• Patch size and patient comfort.
• Manufacturing yield.

Generic or follow-on transdermal products may require more extensive development than conventional tablets. Patent litigation risk is also more concentrated because the commercial product depends on a small number of differentiated systems.

How does granisetron compare with ondansetron and palonosetron?

Attribute	Granisetron	Ondansetron	Palonosetron
Receptor class	5-HT3 antagonist	5-HT3 antagonist	5-HT3 antagonist
Common dosage forms	Tablet, injection, patch	Tablet, ODT, liquid, injection	Injection, oral capsule in some markets
Transdermal option	Yes, Sancuso	No widely established U.S. transdermal equivalent	No widely established U.S. transdermal equivalent
Commercial maturity	High	Very high	High in long-acting IV use
Main differentiation	Multiday patch	Broad generic availability and dosage-form range	Longer duration of action
Excipient opportunity	Patch adhesive, ODT, liquid, ready-to-use injection	Similar, but more crowded	Long-acting and specialty delivery

Granisetron's strongest competitive position is the transdermal route. Ondansetron has greater generic volume and dosage-form breadth. Palonosetron competes through longer receptor activity and dosing convenience in specific chemotherapy settings.

What licensing and manufacturing opportunities exist?

The principal licensing opportunities are:

• Transdermal adhesive technology.
• Pressure-sensitive adhesive platforms.
• Microneedle or enhanced-permeation systems.
• Taste-masking technologies.
• Ready-to-use oncology infusion platforms.
• Contract manufacturing of sterile injectable products.
• Hospital-specific packaging and distribution arrangements.

Manufacturing know-how can be more valuable than a broad composition patent. In transdermal products, adhesive coating uniformity, drying conditions, die cutting, pouch sealing, and stability control are potential barriers. In oral products, the key manufacturing assets are low-dose blending, segregation control, and tablet-content uniformity. For injections, aseptic filling, container compatibility, and extended in-use stability are central.

What is the commercial opportunity for granisetron excipient innovation?

The largest opportunity is a differentiated product for oncology care rather than another commodity tablet.

A prioritized development portfolio would be:

Priority	Product	Rationale
1	Ready-to-use preservative-free injection	Direct hospital workflow benefit
2	Improved transdermal patch	Strongest route-based differentiation
3	Taste-masked oral liquid	Addresses swallowing and outpatient needs
4	Orally disintegrating tablet	Convenient but competitive
5	Standard tablet	Lowest development risk but highest price pressure

Revenue exposure for generic tablets and injections is usually driven by volume and tender wins. A transdermal or specialty product can command better pricing, but its market is narrower and depends on oncology-channel access, reimbursement, and clinical adoption.

Key Takeaways

• Granisetron hydrochloride is a mature active ingredient with limited molecule-level exclusivity.
• Standard tablets and injections face high generic competition and limited pricing power.
• Excipient strategy should focus on content uniformity, rapid disintegration, taste masking, sterility, compatibility, and workflow reduction.
• The transdermal route offers the most defensible formulation differentiation.
• Ready-to-use injections can create commercial value by reducing hospital preparation steps.
• Oral liquids and orally disintegrating tablets address dysphagia and outpatient-use needs.
• Patent protection is most credible for adhesive systems, release control, device integration, manufacturing processes, and demonstrated performance improvements.
• Current Orange Book listings and product-specific litigation must be reviewed before launch, licensing, or Paragraph IV planning.
• A 505(b)(2) strategy is most justified when the formulation provides a measurable administration or adherence advantage.

FAQs

Is granisetron hydrochloride soluble enough for an oral liquid?

Yes. The hydrochloride salt is suitable for aqueous formulation, but pH control, taste masking, preservative selection, and long-term stability require development work.

Can a new granisetron tablet use different excipients from Kytril?

Yes, provided the product meets applicable pharmaceutical equivalence, bioequivalence, quality, stability, and labeling requirements. Different excipients can create a 505(b)(2) issue if they materially affect performance or safety.

Is a granisetron orally disintegrating tablet commercially attractive?

It can be attractive for patients with dysphagia or chemotherapy-related nausea, but the category is more competitive than transdermal delivery. Taste masking and tablet robustness are the principal technical challenges.

Does a granisetron patch need a new clinical trial?

A new patch may require more than conventional bioequivalence testing because transdermal delivery involves adhesion, skin exposure, delivery rate, and clinical performance. The final burden depends on the reference product and the extent of formulation change.

What is the most defensible granisetron formulation patent strategy?

The strongest strategy combines a specific formulation or device claim with comparative performance data showing improved delivery, adhesion, stability, administration convenience, or patient usability.

References

1. U.S. Food and Drug Administration. (1993). Kytril (granisetron hydrochloride) tablets prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Granisetron hydrochloride injection prescribing information.
3. DailyMed. (n.d.). Granisetron hydrochloride injection, solution. National Library of Medicine.
4. U.S. Food and Drug Administration. (2008). Sancuso (granisetron transdermal system) prescribing information.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
6. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.
7. U.S. Courts. (n.d.). PACER case locator and federal court docket records.